Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition

Nature

Volumn 551, Issue 7679, 2017, Pages 247-250

  Hangauer, Matthew J ^a,b,c   Viswanathan, Vasanthi S ^d   Ryan, Matthew J ^d   Bole, Dhruv ^c   Eaton, John K ^d   Matov, Alexandre ^e   Galeas, Jacqueline ^c   Dhruv, Harshil D ^f   Berens, Michael E ^f   Schreiber, Stuart L ^d,g,h   McCormick, Frank ^c   McManus, Michael T ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^e DataSet Analysis LLC   (United States)

^f TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^g HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^h HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; DABRAFENIB; HERMES ANTIGEN; LAPATINIB; PHOSPHOLIPID HYDROPEROXIDE GLUTATHIONE PEROXIDASE; TRAMETINIB; ANTIOXIDANT; GLUTATHIONE PEROXIDASE; IRON; PHOSPHOLIPID-HYDROPEROXIDE GLUTATHIONE PEROXIDASE;

CANCER; CELLS AND CELL COMPONENTS; DRUG RESISTANCE; ENZYME; ENZYME ACTIVITY; INHIBITION; LIPID; TUMOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER RECURRENCE; CELL DEATH; CELL FUNCTION; CONTROLLED STUDY; DRUG TOLERANCE; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OXIDATIVE STRESS; PERSISTER CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; ENZYMOLOGY; MALE; MESODERM; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASM; PATHOLOGY; PRECLINICAL STUDY; RECURRENT DISEASE;

MUS;

ANIMALS; ANTIOXIDANTS; APOPTOSIS; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GLUTATHIONE PEROXIDASE; HUMANS; IRON; MALE; MESODERM; MICE; MOLECULAR TARGETED THERAPY; NEOPLASMS; RECURRENCE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85033481264     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature24297     Document Type: Article

References (23)

1. Groenendijk, F. H. &Bernards, R. Drug resistance to targeted therapies: déjà vu all over again. Mol. Oncol. 8, 1067-1083 (2014)
2. Sharma, S. V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69-80 (2010)
3. Raha, D. et al. The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation. Cancer Res. 74, 3579-3590 (2014)
4. Hata, A. N. et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat. Med. 22, 262-269 (2016)
5. Oxnard, G. R. The cellular origins of drug resistance in cancer. Nat. Med. 22, 232-234 (2016)
6. Viswanathan, V. S. et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature 547, 453-457 (2017)
7. Fan, W. et al. MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents. Cancer Res. 71, 4494-4505 (2011)
8. Yagoda, N. et al. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature 447, 865-869 (2007)
9. Yang, W. S. &Stockwell, B. R. Ferroptosis: death by lipid peroxidation. Trends Cell Biol. 26, 165-176 (2016)
10. Dixon, S. J. et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149, 1060-1072 (2012)
11. Skouta, R. et al. Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J. Am. Chem. Soc. 136, 4551-4556 (2014)
12. Jiang, L. et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature 520, 57-62 (2015)
13. Friedmann Angeli J. P. et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat. Cell Biol. 16, 1180-1191 (2014)
14. Kriska, T., Pilat, A., Schmitt, J. C. &Girotti, A. W. Sterol carrier protein-2 (SCP-2) involvement in cholesterol hydroperoxide cytotoxicity as revealed by SCP-2 inhibitor effects. J. Lipid Res. 51, 3174-3184 (2010)
15. Shimada, K., Hayano, M., Pagano, N. C. &Stockwell, B. R. Cell-line selectivity improves the predictive power of pharmacogenomic analyses and helps identify NADPH as biomarker for ferroptosis sensitivity. Cell Chem. Biol. 23, 225-235 (2016)
16. Yang, W. S. et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 156, 317-331 (2014)
17. Guéraud, F. et al. Chemistry and biochemistry of lipid peroxidation products. Free Radic. Res. 44, 1098-1124 (2010)
18. Shaffer, S. M. et al. Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. Nature 546, 431-435 (2017)
19. Roh, J. L., Kim, E. H., Jang, H. J., Park, J. Y. &Shin, D. Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer. Cancer Lett. 381, 96-103 (2016)
20. Yoo, S. E. et al. Gpx4 ablation in adult mice results in a lethal phenotype accompanied by neuronal loss in brain. Free Radic. Biol. Med. 52, 1820-1827 (2012)
21. Salt, M. B., Bandyopadhyay, S. &McCormick, F. Epithelial-to-mesenchymal transition rewires the molecular path to PI3K-dependent proliferation. Cancer Discov. 4, 186-199 (2014)
22. Gelain, D. P. et al. A systematic review of human antioxidant genes. Front. Biosci. 14, 4457-4463 (2009)
23. Wilson, J. N., Liu, W., Brown, A. S. &Landgraf, R. Binding-induced, turn-on fluorescence of the EGFR/ERBB kinase inhibitor, lapatinib. Org. Biomol. Chem. 13, 5006-5011 (2015)